Hepatic steatosis is a predictor of poor response to interferon alpha-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C.
暂无分享,去创建一个
Y. Takei | N. Sato | K. Ikejima | K. Okumura | Kazuyoshi Kon | Satoko Suzuki | R. Yaginuma
[1] C. Sabin,et al. Insulin Resistance Plays a Significant Role in Liver Fibrosis in Chronic Hepatitis C and in the Response to Antiviral Therapy , 2005, The American Journal of Gastroenterology.
[2] B. Neuschwander‐Tetri,et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[3] Yoshiyuki Suzuki,et al. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN‐resistant cases with hepatocyte steatosis , 2005, Journal of medical virology.
[4] R. Andrade,et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. , 2005, Gastroenterology.
[5] N. Zein. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. , 2005, Journal of hepatology.
[6] D. Dimitropoulou,et al. Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C , 2005, European journal of gastroenterology & hepatology.
[7] O. Chazouilleres,et al. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C , 2005, Hepatology.
[8] A. Sanyal,et al. Hepatitis C and nonalcoholic fatty liver disease. , 2004, Seminars in liver disease.
[9] P. Marcellin,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.
[10] J. McHutchison,et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. , 2004, Journal of hepatology.
[11] L. Rubbia‐Brandt,et al. Steatosis affects chronic hepatitis C progression in a genotype specific way , 2004, Gut.
[12] A. Lonardo,et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. , 2004, Gastroenterology.
[13] A. Greenberg,et al. Adipocytokines and insulin resistance. , 2004, The Journal of clinical endocrinology and metabolism.
[14] S. Kihara,et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. , 2003, Gastroenterology.
[15] R. Stravitz,et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome , 2003, American Journal of Gastroenterology.
[16] M. Manns,et al. Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C , 2003, Hepatology.
[17] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.
[18] J. McHutchison,et al. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C , 2003, Journal of viral hepatitis.
[19] L. Seeff,et al. Natural history of chronic hepatitis C , 2002, Hepatology.
[20] Y. Takei,et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. , 2002, Gastroenterology.
[21] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[22] M. Gambardella,et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.
[23] K. Abid,et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. , 2000, Journal of hepatology.
[24] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.
[25] K Koike,et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. , 1997, The Journal of general virology.
[26] M. Kohara,et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[27] Takao Tsuji,et al. New Inuyama classification; new criteria for histological assessment of chronic hepatitis , 1996 .
[28] E. Larrea,et al. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C , 1996 .
[29] M. Onji,et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[30] Neil Kaplowitz,et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.
[31] E. Esrailian,et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. , 2004, Journal of hepatology.
[32] Y. Jeong,et al. Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .